GlassScriptPhysician profile
Lien Kim B Drew
NPI 1144481912
$16,732.52
in general payments reported to CMS, 2019-2025
36 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $582 · 2021: $1,254 · 2022: $2,273 · 2023: $6,731 · 2024: $2,133 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,907 · Consulting Fee: $3,648 · Travel and Lodging: $385 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,906.92 |
| Consulting Fee | $3,647.50 |
| Travel and Lodging | $385.00 |
| Education | $275.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,002.50 | 2022-2025 | Sotyktu |
| Abbvie INC. | $2,757.42 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $2,720.46 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,075.28 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $829.88 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $779.08 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $685.55 | 2019-2025 | |
| Galderma Laboratories, L.P. | $616.68 | 2019-2025 | Nemluvio, Aklief |
| Ucb, INC. | $567.20 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $546.70 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $378.21 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $344.09 | 2019-2025 | Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $305.41 | 2019-2025 | Dupixent |
| Incyte Corporation | $277.14 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $257.76 | 2020-2025 | Adbry, Anzupgo |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lien Kim Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.